Epirus Biopharmaceuticals announced that it has signed a multi-product, multi-region profit-sharing collaboration with Polpharma Group, for select Epirus biosimilars. The biosimilars covered in the collaboration include BOW015 (infliximab, reference biologic Remicade), BOW050 (adalimumab, reference biologic Humira) and BOW070 (tocilizumab, reference biologic Actemra), which represents $6 billion in innovator sales in the specified territories. With Epirus leading the global product development and clinical programs, both parties will jointly fund clinical development and collaborate on regulatory filings in the specified territories.

Epirus will also be responsible for process development, scale-up and manufacturing, with Polpharma Group overseeing commercialization across the territories. Clinical development costs and eventual operating profit will be split 51% Polpharma Group and 49% Epirus. Polpharma Group will contribute about $30 million towards clinical development costs, as well as cover product launch costs across all three programs. Epirus retains the commercial rights to Switzerland and Norway along with select EU countries including Austria, Belgium, Denmark, Finland, Luxembourg, the Netherlands and Sweden, allowing the company to build its direct commercial footprint.

Epirus also retains rights to North America and other global markets not addressed in this agreement. A joint management board will oversee the collaboration.